The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients

American Journal of Hematology

Volumn 87, Issue 4, 2012, Pages 354-360

  Kelly Sell, Michael J ^a   Kim, Youn H ^b   Straus, Suzanne ^a   Benoit, Bernice ^a   Harrison, Cameron ^b   Sutherland, Katherine ^b   Armstrong, Randall ^b   Weng, Wen Kai ^b   Showe, Louise C ^c   Wysocka, Maria ^a   Rook, Alain H ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b STANFORD UNIVERSITY   (United States)

^c WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; ROMIDEPSIN; TOLL LIKE RECEPTOR AGONIST;

APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELLULAR IMMUNITY; CELLULAR IMMUNODEFICIENCY; CLINICAL ARTICLE; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; CYTOKINE PRODUCTION; CYTOLYSIS; DEGRANULATION; DENDRITIC CELL; DOSE RESPONSE; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; NICK END LABELING; PRIORITY JOURNAL; SEZARY SYNDROME; TUMOR CELL;

ADJUVANTS, IMMUNOLOGIC; APOPTOSIS; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; DEPRESSION, CHEMICAL; DEPSIPEPTIDES; DRUG SCREENING ASSAYS, ANTITUMOR; HISTONE DEACETYLASE INHIBITORS; HUMANS; IMIDAZOLES; IMMUNITY, CELLULAR; INTERFERON-ALPHA; INTERLEUKIN-12; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE COUNT; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 1; NEOPLASM PROTEINS; QUINOLINES; SEZARY SYNDROME; SKIN NEOPLASMS; T-LYMPHOCYTES, REGULATORY; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 8;

EID: 84862777176     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23112     Document Type: Article

References (57)

1. Diamandidou E, Cohen PR, Kurzrock R. Mycosis fungoides and Sezary syndrome. Blood 1996; 88: 2385-2409.
2. Haynes BF, Bunn P, Mann D, et al. Cell surface differentiation antigens of the malignant T cell in Sezary syndrome and mycosis fungoides. J Clin Invest 1981; 67: 523-530.
3. Wood NL, Kitces EN, Blaylock WK. Depressed lymphokine activated killer cell activity in mycosis fungoides. A possible marker for aggressive disease. Arch Dermatol 1990; 126: 907-913.
4. Suchin KR, Cassin M, Gottleib SL, et al. Increased interleukin 5 production in eosinophilic Sezary syndrome: Regulation by interferon alfa and interleukin 12. J Am Acad Dermatol 2001; 44: 28-32.
5. Vowels BR, Cassin M, Vonderheid EC, et al. Aberrant cytokine production by Sezary syndrome patients: Cytokine secretion pattern resembles murine Th2 cells. J Invest Dermatol 1992; 99: 90-94.
6. Vowels BR, Lessin SR, Cassin M, et al. Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma. J Invest Dermatol 1994; 103: 669-673.
7. Asadullah K, Docke WD, Haeussler A, et al. Progression of mycosis fungoides is associated with increasing cutaneous expression of interleukin-10 mRNA. J Invest Dermatol 1996; 107: 833-837.
8. Wysocka M, Zaki MH, French LE, et al. Sezary syndrome patients demonstrate a defect in dendritic cell populations: Effects of CD40 ligand and treatment with GM-CSF on dendritic cell numbers and the production of cytokines. Blood 2002; 100: 3287-3294.
9. Rook AH, Wood GS, Yoo EK, et al. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 1999; 94: 902-908.
10. Wood GS. Lymphocyte activation in cutaneous T-cell lymphoma. J Invest Dermatol 1995; 105: 105S-109S.
11. Raphael BA, Shin DB, Suchin KR, et al. High clinical response rate of Sezary syndrome to immunomodulatory therapies: Prognostic markers of response. Arch Dermatol 2011; 147: 1410-1415.
12. Richardson SK, Lin JH, Vittorio CC, et al. High clinical response rate with multimodality immunomodulatory therapy for Sezary syndrome. Clin Lymphoma Myeloma 2006; 7: 226-232.
13. Rook AH, Kuzel TM, Olsen EA. Cytokine therapy of cutaneous T-cell lymphoma: Interferons, interleukin-12, and interleukin-2. Hematol Oncol Clin North Am 2003; 17: 1435-1448, ix.
14. Ito T, Amakawa R, Kaisho T, et al. Interferon-alpha and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets. J Exp Med 2002; 195: 1507-1512.
15. Wysocka M, Dawany N, Benoit B, et al. Synergistic enhancement of cellular immune responses by the novel Toll receptor 7/8 agonist 3M-007 and interferon-γ: Implications for therapy of cutaneous T-cell lymphoma. Leuk Lymphoma 2011; 52: 1970-1979.
16. Bunn PAJr, Hoffman SJ, Norris D, et al. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome). Ann Intern Med 1994; 121: 592-602.
17. Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009; 27: 5410-5417.
18. Whittaker SJ, Demierre MF, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 2010; 28: 4485-4491.
19. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6: 38-51.
20. Richon VM, Garcia-Vargas J, Hardwick JS. Development of vorinostat: Current applications and future perspectives for cancer therapy. Cancer Lett 2009; 280: 201-210.
21. Vrana JA, Decker RH, Johnson CR, et al. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene 1999; 18: 7016-7025.
22. Roger T, Lugrin J, Le Roy D, et al. Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection. Blood 2011; 117: 1205-1217.
23. Ogbomo H, Michaelis M, Kreuter J, et al. Histone deacetylase inhibitors suppress natural killer cell cytolytic activity. FEBS Lett 2007; 581: 1317-1322.
24. Song W, Tai YT, Tian Z, et al. HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells. Leukemia 2011; 25: 161-168.
25. Anshelevich A, Wysocka M, Benoit BM, et al. Minimizing the immunosuppressive effects of histone deacetylase inhibitors (HDACi): Implications for therapy of cutaneous T-cell lymphoma (CTCL). First World Congress of Cutaneous Lymphomas. Chicago, IL; 2010.
26. Ritchie D, Piekarz RL, Blombery P, et al. Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: A case series report. Haematologica 2009; 94: 1618-1622.
27. Akimova T, Ge G, Golovina T, et al. Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs. Clin Immunol 2010; 136: 348-363.
28. Gardner JM, Evans KG, Goldstein S, et al. Vorinostat for the treatment of bullous pemphigoid in the setting of advanced, refractory cutaneous T-cell lymphoma. Arch Dermatol 2009; 145: 985-988.
29. Glauben R, Batra A, Fedke I, et al. Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J Immunol 2006; 176: 5015-5022.
30. Mishra N, Reilly CM, Brown DR, et al. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J Clin Invest 2003; 111: 539-552.
31. Reilly CM, Mishra N, Miller JM, et al. Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid. J Immunol 2004; 173: 4171-4178.
32. Shakespear MR, Halili MA, Irvine KM, et al. Histone deacetylases as regulators of inflammation and immunity. Trends Immunol 2011; 32: 335-343.
33. Murphy GF. Cutaneous T-cell lymphoma. Adv Pathol 1988; 1: 131-156.
34. Introcaso CE, Hess SD, Kamoun M, et al. Association of change in clinical status and change in the percentage of the CD4+CD26- lymphocyte population in patients with Sezary syndrome. J Am Acad Dermatol 2005; 53: 428-434.
35. Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 1713-1722.
36. Celgene Corporation. Istodax (romidepsin) prescribing information. Summit, NJ; 2011.
37. Betts MR, Brenchley JM, Price DA, et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003; 281: 65-78.
38. Uhrberg M. The CD107 mobilization assay: Viable isolation and immunotherapeutic potential of tumor-cytolytic NK cells. Leukemia 2005; 19: 707-709.
39. Aung HT, Schroder K, Himes SR, et al. LPS regulates proinflammatory gene expression in macrophages by altering histone deacetylase expression. FASEB J 2006; 20: 1315-1327.
40. Bode KA, Schroder K, Hume DA, et al. Histone deacetylase inhibitors decrease Toll-like receptor-mediated activation of proinflammatory gene expression by impairing transcription factor recruitment. Immunology 2007; 122: 596-606.
41. Brogdon JL, Xu Y, Szabo SJ, et al. Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood 2007; 109: 1123-1130.
42. Chang HM, Paulson M, Holko M, et al. Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity. Proc Natl Acad Sci USA 2004; 101: 9578-9583.
43. Kramer OH, Knauer SK, Greiner G, et al. A phosphorylation-acetylation switch regulates STAT1 signaling. Genes Dev 2009; 23: 223-235.
44. Nusinzon I, Horvath CM. Positive and negative regulation of the innate antiviral response and beta interferon gene expression by deacetylation. Mol Cell Biol 2006; 26: 3106-3113.
45. Villagra A, Cheng F, Wang HW, et al. The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat Immunol 2009; 10: 92-100.
46. Bradner JE, West N, Grachan ML, et al. Chemical phylogenetics of histone deacetylases. Nat Chem Biol 2010; 6: 238-243.
47. Furumai R, Matsuyama A, Kobashi N, et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 2002; 62: 4916-4921.
48. Wang L, Tao R, Hancock WW. Using histone deacetylase inhibitors to enhance Foxp3(+) regulatory T-cell function and induce allograft tolerance. Immunol Cell Biol 2009; 87: 195-202.
49. Chung YL, Lee MY, Wang AJ, et al. A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol Ther 2003; 8: 707-717.
50. Reddy P, Maeda Y, Hotary K, et al. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci USA 2004; 101: 3921-3926.
51. Choi JH, Oh SW, Kang MS, et al. Trichostatin A attenuates airway inflammation in mouse asthma model. Clin Exp Allergy 2005; 35: 89-96.
52. Reddy P, Sun Y, Toubai T, et al. Histone deacetylase inhibition modulates indoleamine 2, 3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J Clin Invest 2008; 118: 2562-2573.
53. Li N, Zhao D, Kirschbaum M, et al. HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen. Proc Natl Acad Sci USA 2008; 105: 4796-4801.
54. Zhang C, Richon V, Ni X, et al. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: Relevance to mechanism of therapeutic action. J Invest Dermatol 2005; 125: 1045-1052.
55. Moreira JM, Scheipers P, Sorensen P. The histone deacetylase inhibitor Trichostatin A modulates CD4+ T cell responses. BMC Cancer 2003; 3: 30.
56. Gardner JM, Introcaso CE, Nasta SD, et al. A novel regimen of vorinostat with interferon gamma for refractory Sezary syndrome. J Am Acad Dermatol 2009; 61: 112-116.
57. Wysocka M, Newton S, Benoit BM, et al. Synthetic imidazoquinolines potently and broadly activate the cellular immune response of patients with cutaneous T-cell lymphoma: Synergy with interferon-gamma enhances production of interleukin-12. Clin Lymphoma Myeloma 2007; 7: 524-534.